WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005037235) FIBROBLAST GROWTH FACTOR RECEPTOR-1 INHIBITORS AND METHODS OF TREATMENT THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2005/037235 International Application No.: PCT/US2004/034970
Publication Date: 28.04.2005 International Filing Date: 18.10.2004
IPC:
A61K 39/395 (2006.01)
Applicants: SUN, Haijun[CN/US]; US (UsOnly)
SHEN, Juqun[CA/US]; US (UsOnly)
TONRA, James, R.[US/US]; US (UsOnly)
IMCLONE SYSTEMS INCORPORATED[US/US]; 180 Varick Street New York, NY 10014, US (AllExceptUS)
Inventors: SUN, Haijun; US
SHEN, Juqun; US
TONRA, James, R.; US
Agent: SOMERVILLE, Deborah, A. ; Kenyon & Kenyon One Broadway New York, NY 10004, US
Priority Data:
60/512,25516.10.2003US
Title (EN) FIBROBLAST GROWTH FACTOR RECEPTOR-1 INHIBITORS AND METHODS OF TREATMENT THEREOF
(FR) INHIBITEURS DU RECEPTEUR 1 DU FACTEUR DE CROISSANCE DU FIBROBLASTE ET METHODES THERAPEUTIQUES ASSOCIEES
Abstract:
(EN) The present invention is directed to an antibody or fragments thereof that are specific for a fibroblast growth factor receptor (FGFR)-1(IIIb), FGFR-1(IIIc), and/or FGFR-4. Also, provided herein, are vectors and host cells comprising the nucleic acids encoding those antibodies. The present invention further provides methods of antagonizing FGFR-1 or FGFR-4 as a treatment for obesity, diabetes, or a condition related thereto, and methods of reducing food intake.
(FR) L'invention concerne un anticorps ou des fragments d'anticorps spécifiques du récepteur du facteur de croissance du fibroblaste (FGFR)-1(IIIb), FGFR-1(IIIc) et/ou FGFR-4. L'invention concerne également des vecteurs et des cellules hôtes contenant les acides nucléiques codant ces anticorps. L'invention concerne encore des méthodes destinées à antagoniser FGFR-1 ou FGFR-4, utilisées dans le traitement de l'obésité, du diabète ou d'un état associé, ainsi que des méthodes visant à réduire la prise alimentaire.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)